Venus Remedies Ltd(VENUSREM)

NSE: VENUSREMBSE: 526953

₹ 1,465+4.92%refreshed 26 Oct, 03:30 pm ISTMarket cap: ₹ 1,958 crNext results: 26 Oct 2026Website: www.venusremedies.comUpdated: 27 Oct 2026

About

Venus Remedies Ltd is an Indian pharmaceutical company specialising in sterile injectable formulations, with consolidated revenue of ₹769.60 Cr in FY26 (up 17.87% from ₹652.89 Cr in FY25). International operations accounted for 77% of total revenue across 100+ markets in FY26. The company operates on a zero-debt balance sheet and runs an in-house R&D centre (VMRC) focused on novel anti-infectives and other therapeutic areas.^[1][2]

Business segments

The group operates in a single segment - Pharmaceutical Formulation - generating revenue of ₹647.89 Cr in FY25.^[3]
International business crossed ₹590+ Cr in FY26 (up from ₹468 Cr in FY25), representing 77% of total consolidated revenue.^[1]

Products and portfolio

Sterile injectable portfolio spans dry-powder antibiotics, oncology dry-powder injectables, general sterile injectables, pre-filled syringes (PFS), and specialty hospital therapies.^[1]
RESET is a plant-based wellness consumer healthcare brand covering five verticals: RESET Pain Relief, RESET Wellness, RESET Vitals, RESET Yoga and RESET Detox.^[1]
As of March 31, 2026, the company held 1,100+ marketing authorisations worldwide, of which 511+ are commercially active.^[1]
As of March 31, 2026, Venus Remedies held 150+ patents granted globally, 125+ registered trademarks, and 17+ copyrights.^[1]

Manufacturing operations

Unit-I is located at Plot 51-52, Industrial Area, Phase-I, Panchkula; Unit-II at Hill Top Industrial Estate, Jharmajri EPIP, Baddi, Himachal Pradesh.^[1]
The Venus Global Fulfillment Centre (VGFC) spans 66,000 sq ft with 5,000 pallet positions, with IoT tracking at rack, shelf and pallet levels.^[1]
As of March 31, 2026, the workforce comprised 1,472 employees across 5 locations; women represented 16% of the total workforce and average employee age was 35 years.^[1]

R&D pipeline

VMRC's pipeline spans 9 candidates across 6 therapy areas: anti-infectives, gut health, metabolic health, pain management, skin and wound care.^[1]
VRP-034 received CDSCO approval; Phase 1 clinical patient dosing begins Q1 FY27. The candidate holds USFDA QIDP designation and its patent has been filed in 88+ countries with 15 grants.^[1]
VRP-048 (second USFDA QIDP candidate) has completed preclinical work; CDSCO CTA filing is expected within 4 - 6 quarters from FY26.^[1]
Renal Guard Technology (RGT), a proprietary platform to reduce nephrotoxicity from potent antibiotics such as polymyxin, was developed in FY25.^[3]
Gene-editing programs were initiated in FY25 to combat antimicrobial resistance at a genetic level.^[3]

Geography and distribution

Latin America was the largest export market at 24.2% of international revenue in FY26, followed by Europe at 22.6%; Asia, Africa and the Middle East collectively contributed 51.60%.^[1]
90 first market-authorisation grants were secured across 33 country-product combinations in FY26, including Sugammadex in the Philippines and Fulvestrant in Saudi Arabia.^[1]

Customers and contract manufacturing

Contract manufacturing partners include Cipla, Zydus Life Sciences, Intas Pharmaceuticals, Ajanta Pharma and Lupin.^[1]
Two Venus formulations were approved under the ESI framework in FY26; the company supplied 74 ESI hospitals across India.^[1]

Expansion and capex

A new headquarters and Innovation Centre is under construction and due for completion in FY27.^[1]
Venus Industrial Park (VIP), a greenfield EHS-first site, is planned under Mission 2030; construction to begin within the Mission 2030 window with production targeted by 2030.^[1]
Near-term capacity growth is expected from existing plants through productivity, automation and digitalisation rather than new facilities.^[1]

Recent developments

Mission 2030 was unveiled in March 2026, comprising ten missions across science, manufacturing, commercial growth, digital transformation, sustainability and institutional capability.^[1]
The board recommended a final dividend of ₹10 per share for FY26 - the company's first shareholder payout in over a decade.^[1]
ICD Online, described as an industry-first integrated production and inventory planning platform within Indian pharmaceuticals, simultaneously schedules all orders across 100+ countries in a single optimised flow.^[1]
Venus Pharma GmbH (German subsidiary) reported a loss of ₹729.03 lakhs in FY25 on total income of ₹3,870.30 lakhs, down sharply from total income of ₹11,320.95 lakhs in FY24.^[3]

Market Cap

₹1,958 Cr

High / Low

₹2,043 / 432

Stock P/E

16.3

Price / Book

2.9

Book Value

₹497

EPS

₹76.9

No. of Shares

1.34 Cr

ROCE

21.9%

ROE

16.8%

OPM

17.2%

Debt / Equity

0.00

Sales

₹770 Cr

Net Profit

₹103 Cr

Promoter holding

41.8%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

No earnings calls are on record for this company, so our models read its annual report and financials end-to-end - then value the business and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
P&L bridge from reported history - worst / average / best multiple cases.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials